News

The decision is driven by recent findings derived from a non-interventional human study utilizing a clinically validated CANscript platform. GBR 1342 is based on Glenmark’s proprietary BEAT platform

This name reflects the company’s focus on advancing the science of cytokine-based immunotherapy for the treatment of a range of cancers. Brooklyn ImmunoTherapeutics general partner and board chair

Mirum Pharmaceuticals is focused on the development of an approach for treating cholestatic liver diseases, with an immediate focus on rare pediatric conditions. Maralixibat is under development for

The Switzerland-based Covis Pharma will also make conditional sales-related payments for the three over-the-counter (OTC) drugs of up to $21m over four years from 2019. AstraZeneca global product

The positive topline results of the phase 3 ECHELON-2 clinical trial were announced in October 2018 and full data will be presented at the upcoming American Society of

GKT831 recorded high statistical significance following six weeks of treatment, said the French biotech company. The 24-week placebo-controlled trial is being held across multiple countries in 111 PBC

IPI-549 is an oral immuno-oncology development candidate, which is designed to selectively inhibit phosphoinositide-3-kinase (PI3K)-gamma. It is claimed to be the only investigational PI3K-gamma inhibitor in clinical development.

The program’s investment has tripled the site’s GMP capacity, added new equipment for solid oral dose manufacturing and significantly increased staffing levels. Quotient Sciences CEO Mark Egerton said:

Lorbrena is a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) to treat patients with ALK-positive metastatic NSCLC whose disease has progressed on crizotinib and at least